Advances in the study of LNPs for mRNA delivery and clinical applications

被引：6

作者：

Wang, Bili ^{[1
]}

Shen, Biao ^{[2
]}

Xiang, Wenqing ^{[1
]}

Shen, Hongqiang ^{[1
]}

机构：

[1] Zhejiang Univ, Childrens Hosp,Sch Med, Natl Clin Res Ctr Child Hlth, Natl Childrens Reg Med Ctr, Hangzhou 310052, Peoples R China

[2] Hangzhou Cybernax Biotechnol Co Ltd, Hangzhou 311202, Peoples R China

来源：

VIRUS GENES | 2024年 / 60卷 / 06期

关键词：

LNPs; mRNA vaccines; mRNA delivery; Clinical applications; LIPID NANOPARTICLE FORMULATIONS; IN-VIVO; CANCER VACCINES; CATIONIC LIPIDS; RESPONSES; OPTIMIZATION; CHOLESTEROL; POTENCY; CELLS; SIRNA;

D O I：

10.1007/s11262-024-02102-6

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

Messenger ribonucleic acid (mRNA) was discovered in 1961 as an intermediary for transferring genetic information from DNA to ribosomes for protein synthesis. The COVID-19 pandemic brought worldwide attention to mRNA vaccines. The emergency use authorization of two COVID-19 mRNA vaccines, BNT162b2 and mRNA-1273, were major achievements in the history of vaccine development. Lipid nanoparticles (LNPs), one of the most superior non-viral delivery vectors available, have made many exciting advances in clinical translation as part of the COVID-19 vaccine and therefore has the potential to accelerate the clinical translation of many gene drugs. In addition, due to these small size, biocompatibility and excellent biodegradability, LNPs can efficiently deliver nucleic acids into cells, which is particularly important for current mRNA therapeutic regimens. LNPs are composed cationic or pH-dependent ionizable lipid bilayer, polyethylene glycol (PEG), phospholipids, and cholesterol, represents an advanced system for the delivery of mRNA vaccines. Furthermore, optimization of these four components constituting the LNPs have demonstrated enhanced vaccine efficacy and diminished adverse effects. The incorporation of biodegradable lipids enhance the biocompatibility of LNPs, thereby improving its potential as an efficacious therapeutic approach for a wide range of challenging and intricate diseases, encompassing infectious diseases, liver disorders, cancer, cardiovascular diseases, cerebrovascular conditions, among others. Consequently, this review aims to furnish the scientific community with the most up-to-date information regarding mRNA vaccines and LNP delivery systems.

引用

页码：577 / 591

页数：15

共 110 条

[1] Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms [J].

Akinc, Akin ;

Querbes, William ;

De, Soma ;

Qin, June ;

Frank-Kamenetsky, Maria ;

Jayaprakash, K. Narayanannair ;

Jayaraman, Muthusamy ;

Rajeev, Kallanthottathil G. ;

Cantley, William L. ;

Dorkin, J. Robert ;

Butler, James S. ;

Qin, LiuLiang ;

Racie, Timothy ;

Sprague, Andrew ;

Fava, Eugenio ;

Zeigerer, Anja ;

Hope, Michael J. ;

Zerial, Marino ;

Sah, Dinah W. Y. ;

Fitzgerald, Kevin ;

Tracy, Mark A. ;

Manoharan, Muthiah ;

Koteliansky, Victor ;

de Fougerolles, Antonin ;

Maier, Martin A. .

MOLECULAR THERAPY, 2010, 18 (07) :1357-1364

[2] Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses [J].

Alameh, Mohamad-Gabriel ;

Tombacz, Istvan ;

Bettini, Emily ;

Lederer, Katlyn ;

Sittplangkoon, Chutamath ;

Wilmore, Joel R. ;

Gaudette, Brian T. ;

Soliman, Ousamah Y. ;

Pine, Matthew ;

Hicks, Philip ;

Manzoni, Tomaz B. ;

Knox, James J. ;

Johnson, John L. ;

Laczko, Dorottya ;

Muramatsu, Hiromi ;

Davis, Benjamin ;

Meng, Wenzhao ;

Rosenfeld, Aaron M. ;

Strohmeier, Shirin ;

Lin, Paulo J. C. ;

Mui, Barbara L. ;

Tam, Ying K. ;

Kariko, Katalin ;

Jacquet, Alain ;

Krammer, Florian ;

Bates, Paul ;

Cancro, Michael P. ;

Weissman, Drew ;

Prak, Eline T. Luning ;

Allman, David ;

Locci, Michela ;

Pardi, Norbert .

IMMUNITY, 2021, 54 (12) :2877-+

[3] Lipid Nanoparticles as Delivery Systems for RNA-Based Vaccines [J].

Aldosari, Basmah N. ;

Alfagih, Iman M. ;

Almurshedi, Alanood S. .

PHARMACEUTICS, 2021, 13 (02) :1-29

[4] Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults [J].

Anderson, E. J. ;

Rouphael, N. G. ;

Widge, A. T. ;

Jackson, L. A. ;

Roberts, P. C. ;

Makhene, M. ;

Chappell, J. D. ;

Denison, M. R. ;

Stevens, L. J. ;

Pruijssers, A. J. ;

McDermott, A. B. ;

Flach, B. ;

Lin, B. C. ;

Doria-Rose, N. A. ;

O'Dell, S. ;

Schmidt, S. D. ;

Corbett, K. S. ;

Swanson, P. A., II ;

Padilla, M. ;

Neuzil, K. M. ;

Bennett, H. ;

Leav, B. ;

Makowski, M. ;

Albert, J. ;

Cross, K. ;

Edara, V. V. ;

Floyd, K. ;

Suthar, M. S. ;

Martinez, D. R. ;

Baric, R. ;

Buchanan, W. ;

Luke, C. J. ;

Phadke, V. K. ;

Rostad, C. A. ;

Ledgerwood, J. E. ;

Graham, B. S. ;

Beigel, J. H. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (25) :2427-2438

[5] Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine [J].

Baden, Lindsey R. ;

El Sahly, Hana M. ;

Essink, Brandon ;

Kotloff, Karen ;

Frey, Sharon ;

Novak, Rick ;

Diemert, David ;

Spector, Stephen A. ;

Rouphael, Nadine ;

Creech, C. Buddy ;

McGettigan, John ;

Khetan, Shishir ;

Segall, Nathan ;

Solis, Joel ;

Brosz, Adam ;

Fierro, Carlos ;

Schwartz, Howard ;

Neuzil, Kathleen ;

Corey, Larry ;

Gilbert, Peter ;

Janes, Holly ;

Follmann, Dean ;

Marovich, Mary ;

Mascola, John ;

Polakowski, Laura ;

Ledgerwood, Julie ;

Graham, Barney S. ;

Bennett, Hamilton ;

Pajon, Rolando ;

Knightly, Conor ;

Leav, Brett ;

Deng, Weiping ;

Zhou, Honghong ;

Han, Shu ;

Ivarsson, Melanie ;

Miller, Jacqueline ;

Zaks, Tal .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (05) :403-416

[6] Inside out: optimization of lipid nanoparticle formulations for exterior complexation and in vivo delivery of saRNA [J].

Blakney, Anna K. ;

McKay, Paul F. ;

Yus, Barbara Ibarzo ;

Aldon, Yoann ;

Shattock, Robin J. .

GENE THERAPY, 2019, 26 (09) :363-372

[7] Nanomaterial Delivery Systems for mRNA Vaccines [J].

Buschmann, Michael D. ;

Carrasco, Manuel J. ;

Alishetty, Suman ;

Paige, Mikell ;

Alameh, Mohamad Gabriel ;

Weissman, Drew .

VACCINES, 2021, 9 (01) :1-30

[8] Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA [J].

Chen, Sam ;

Tam, Yuen Yi C. ;

Lin, Paulo J. C. ;

Sung, Molly M. H. ;

Tam, Ying K. ;

Cullis, Pieter R. .

JOURNAL OF CONTROLLED RELEASE, 2016, 235 :236-244

[9] Who discovered messenger RNA? [J].

Cobb, Matthew .

CURRENT BIOLOGY, 2015, 25 (13) :R526-R532

[10] Addressing the Cold Reality of mRNA Vaccine Stability [J].

Crommelin, Daan J. A. ;

Anchordoquy, Thomas J. ;

Volkin, David B. ;

Jiskoot, Wim ;

Mastrobattista, Enrico .

JOURNAL OF PHARMACEUTICAL SCIENCES, 2021, 110 (03) :997-1001

← 1 2 3 4 5 6 7 8 9 10 →